尽管基因编辑领域形势艰难，但一家公司却引起了一些关注并获得了资金。总部位于剑桥的 Arbor 生物技术公司已经获得了 7350 万美元的 C 轮融资，用于推进其基于 CRISPR 的基因治疗产品线，目标是肝脏和中枢神经系统。

Arbor Biotechnologies has closed $73.9m in a Series C financing round, earmarked for advancing its gene editing therapeutic pipeline aimed at liver and central nervous system diseases. TCGX and ARCH ...

The arbor is traditionally used to define a pathway ... Bore countersink holes if needed. Cut the 2x12 arch material to ...

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into 2027 and supports the clinical ...